Publication | Closed Access

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Cardiovascular DiseasePcsk9 Inhibitor EvolocumabPharmacologyClinical TrialsHyperlipidemiaPharmacotherapyFourier TrialLipoprotein MetabolismMedicineClinical EfficacyAtherosclerosisDyslipidemia